Yutong Geng

Program: Molecular Cell Biology

Current advisor: Kian Lim, MD, PhD

Undergraduate university: Central China Normal University, 2022

Enrollment year: 2024

Research summary

Graduate publications
Bansod SP, Hung-Po Chen T, Somani VK, Li L, Geng Y, Wang Y, Bulle A, Modekurty S, Knolhoff BL, Fields RC, Ruzinova MB, DeNardo DG, Lim KH. 2026 Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Gastroenterology, ():S0016-5085(26)06766-1. PMCID: PMC13286625

Somani VK, Zhang X, Chen TH, Bulle A, Bansod S, Li L, Geng Y, Kang LI, Heo GS, Luehmann H, Zhang Y, Saeed MA, Lavine KJ, DeNardo DG, Pachynski RK, Liu Y, Lim KH. 2026 Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic. Mol Cancer, 25(1):65. PMCID: PMC12977780

Bansod S, Dodhiawala PB, Geng Y, Bulle A, Liu P, Li L, Townsend R, Grierson PM, Held JM, Adhikari H, Lim KH. 2024 The TRIM4 E3 ubiquitin ligase degrades TPL2 and is modulated by oncogenic KRAS. Cell Rep, 43(9):114667. PMCID: PMC11472288

Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, Somani V, Khawar IA, Chen HP, Dodhiawala PB, Li L, Geng Y, Mo CK, Mahsl J, Ding L, Govindan R, Davies S, Mudd J, Hawkins WG, Fields RC, DeNardo DG, Knoerzer D, Held JM, Grierson PM, Wang-Gillam A, Ruzinova MB, Lim KH. 2024 Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Nat Commun, 15(1):2503. PMCID: PMC10954758

Bulle A, Chen Y, Li H, Chen TH, Khawar IA, Li L, Wang Y, Liu P, Somani VK, Kurupi R, Geng Y, Pereye OB, Bansod S, Le SB, Ruzinova MB, Tran DD, Lim KH. Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. Cancer Res, 86(13):3270-86. PMCID: PMC13101933